Abstract
In recent years, quantitative evaluation for biosimilarity has been taken seriously due to the development of biosimilar products. The concept for assessment of biological products is very different from that of small-molecule drug products because of the variability with respect to the manufacturing process and environmental factors of the biological products. In this article, we propose an estimate method for a biosimilar index and the related lower bound based on the concept of reproducibility probability by assessing power. In addition, some approximations are proposed and compared in regard to simplicity and accuracy.
| Original language | English |
|---|---|
| Pages (from-to) | 1298-1311 |
| Number of pages | 14 |
| Journal | Journal of Biopharmaceutical Statistics |
| Volume | 24 |
| Issue number | 6 |
| DOIs | |
| State | Published - 02 11 2014 |
Bibliographical note
Publisher Copyright:Copyright © 2014 Taylor & Francis Group, LLC.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 9 Industry, Innovation, and Infrastructure
Keywords
- Biosimilar index
- Biosimilarity
- Lower bound
- Noncentral t-approximation
- Power estimation
Fingerprint
Dive into the research topics of 'Estimation and approximation approaches for biosimilar index based on reproducibility probability'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver